NVCT Nuvectis Pharma Inc.: Earnings per share for the last 12 months

Nuvectis (NVCT) - corporate logo

Nuvectis Pharma, Inc. (NVCT) relies on a strong team of biochemists whose commitment is sustained by a stock option system. However, investors should consider the uncertainty of early clinical trials and the lack of consistent profit. The market capitalization trend reflects the current figure of -40.40. The business is based on developing targeted tumor treatments for oncology centers, focusing on blocking proteins that trigger the development of aggressive neoplasms.

Nuvectis (NVCT) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/18/2026

NVCT (Nuvectis Pharma Inc.): analytical breakdowns and indicator data

- company stock capitalization data:
Fundamental company valuation:NVCT Nuvectis
Flagship merchandise of Nuvectis Pharma

For Nuvectis Pharma, Inc. (NVCT), which is developing targeted oncology therapies, earnings per share dynamics serve as a key indicator of how effectively the company capitalizes on its innovations. This metric measures the percentage change in EPS over the last twelve months relative to the same period last year, reflecting the growth or contraction rates of net income. Comparing year-over-year EPS (TTM) allows for an assessment of whether the financial momentum justifies the high level of confidence from the medical community. This analysis warns investors against overpaying for the asset if operational efficiency begins to fade.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NUVB|DAWN (dayonebio.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months monopartx.com (MNPR)|Earnings per share for the last twelve months Inhibrx Corp (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months